- Home
- BBIO vs VANI Comparison
BBIO vs VANI Comparison
Compare BBIO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- VANI
- Stock Information
- Founded
- BBIO 2015
- VANI 1998
- Country
- BBIO United States
- VANI United States
- Employees
- BBIO N/A
- VANI N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BBIO Health Care
- VANI Health Care
- Exchange
- BBIO Nasdaq
- VANI Nasdaq
- Market Cap
- BBIO 8.0B
- VANI 75.2M
- IPO Year
- BBIO 2019
- VANI 2014
- Fundamental
- Price
- BBIO $46.47
- VANI $1.40
- Analyst Decision
- BBIO Strong Buy
- VANI Strong Buy
- Analyst Count
- BBIO 14
- VANI 1
- Target Price
- BBIO $60.21
- VANI $4.00
- AVG Volume (30 Days)
- BBIO 3.4M
- VANI 141.6K
- Earning Date
- BBIO 07-31-2025
- VANI 08-12-2025
- Dividend Yield
- BBIO N/A
- VANI N/A
- EPS Growth
- BBIO N/A
- VANI N/A
- EPS
- BBIO N/A
- VANI N/A
- Revenue
- BBIO $127,415,000.00
- VANI N/A
- Revenue This Year
- BBIO $107.34
- VANI N/A
- Revenue Next Year
- BBIO $49.48
- VANI N/A
- P/E Ratio
- BBIO N/A
- VANI N/A
- Revenue Growth
- BBIO N/A
- VANI N/A
- 52 Week Low
- BBIO $21.72
- VANI $0.91
- 52 Week High
- BBIO $46.80
- VANI $1.50
- Technical
- Relative Strength Index (RSI)
- BBIO 71.64
- VANI 74.26
- Support Level
- BBIO $41.80
- VANI $1.26
- Resistance Level
- BBIO $46.80
- VANI $1.30
- Average True Range (ATR)
- BBIO 1.44
- VANI 0.06
- MACD
- BBIO 0.09
- VANI 0.00
- Stochastic Oscillator
- BBIO 94.00
- VANI 69.70
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.